FR2997302B1 - Prevention et traitement des deficits en pyruvate deshydrogenase - Google Patents

Prevention et traitement des deficits en pyruvate deshydrogenase

Info

Publication number
FR2997302B1
FR2997302B1 FR1260304A FR1260304A FR2997302B1 FR 2997302 B1 FR2997302 B1 FR 2997302B1 FR 1260304 A FR1260304 A FR 1260304A FR 1260304 A FR1260304 A FR 1260304A FR 2997302 B1 FR2997302 B1 FR 2997302B1
Authority
FR
France
Prior art keywords
deficits
prevention
treatment
pyruvate deshydrogenase
deshydrogenase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR1260304A
Other languages
English (en)
Other versions
FR2997302A1 (fr
Inventor
Lonlay Pascale De
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Assistance Publique Hopitaux de Paris APHP
Original Assignee
Assistance Publique Hopitaux de Paris APHP
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Assistance Publique Hopitaux de Paris APHP filed Critical Assistance Publique Hopitaux de Paris APHP
Priority to FR1260304A priority Critical patent/FR2997302B1/fr
Publication of FR2997302A1 publication Critical patent/FR2997302A1/fr
Application granted granted Critical
Publication of FR2997302B1 publication Critical patent/FR2997302B1/fr
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A61K31/51—Thiamines, e.g. vitamin B1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
FR1260304A 2012-10-29 2012-10-29 Prevention et traitement des deficits en pyruvate deshydrogenase Expired - Fee Related FR2997302B1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
FR1260304A FR2997302B1 (fr) 2012-10-29 2012-10-29 Prevention et traitement des deficits en pyruvate deshydrogenase

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1260304A FR2997302B1 (fr) 2012-10-29 2012-10-29 Prevention et traitement des deficits en pyruvate deshydrogenase

Publications (2)

Publication Number Publication Date
FR2997302A1 FR2997302A1 (fr) 2014-05-02
FR2997302B1 true FR2997302B1 (fr) 2015-02-06

Family

ID=47833126

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1260304A Expired - Fee Related FR2997302B1 (fr) 2012-10-29 2012-10-29 Prevention et traitement des deficits en pyruvate deshydrogenase

Country Status (1)

Country Link
FR (1) FR2997302B1 (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11241403B2 (en) 2016-03-11 2022-02-08 Axcess Global Sciences, Llc Beta-hydroxybutyrate mixed salt compositions and methods of use
US11103470B2 (en) 2017-11-22 2021-08-31 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
US12533346B2 (en) 2016-04-19 2026-01-27 Axcess Global Sciences, Llc Administration of berberine metabolites
US12329734B2 (en) 2017-12-19 2025-06-17 Axcess Global Sciences, Llc Use of S-beta-hydroxybutyrate compounds for induction and maintenance of flow
US10925843B2 (en) 2018-04-18 2021-02-23 Axcess Global Sciences, Llc Compositions and methods for keto stacking with beta-hydroxybutyrate and acetoacetate
US12599579B2 (en) 2016-04-19 2026-04-14 Axcess Global Sciences, Llc Compositions and compounds containing ketone bodies and/or ketone body precursors and one or more amino acids
US12496283B2 (en) 2016-04-19 2025-12-16 Axcess Global Sciences, Llc Administration of R-beta-hydroxybutyrate and related compounds in humans
US20230346721A1 (en) 2018-04-18 2023-11-02 Axcess Global Sciences, Llc Beta-hydroxybutyric acid compositions and methods for delivery of ketone bodies
US11944598B2 (en) 2017-12-19 2024-04-02 Axcess Global Sciences, Llc Compositions containing s-beta-hydroxybutyrate or non-racemic mixtures enriched with the s-enatiomer
US12109182B2 (en) 2016-04-19 2024-10-08 Axcess Global Sciences, Llc Administration of R-beta-hydroxybutyrate and related compounds in humans
US12521378B2 (en) 2016-04-19 2026-01-13 Axcess Global Sciences, Llc Administration of R-beta-hydroxybutyrate salt blend and related compounds in humans
US11202769B2 (en) 2017-11-22 2021-12-21 Axcess Global Sciences, Llc Ketone body esters of s-beta-hydroxybutyrate and/or s-1,3-butanediol for modifying metabolic function
US11806324B2 (en) 2018-04-18 2023-11-07 Axcess Global Sciences, Llc Beta-hydroxybutyric acid compositions and methods for oral delivery of ketone bodies
US20180177753A1 (en) 2016-12-23 2018-06-28 Neuroenergy Ventures, Inc. Glyceryl 3-hydroxybutyrates for migraine symptom management
US9925164B1 (en) 2017-01-12 2018-03-27 Neuroenergy Ventures, Inc. Glyceryl 3-hydroxybutyrates for traumatic brain injury
US12090129B2 (en) 2017-11-22 2024-09-17 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
US12472200B2 (en) 2019-05-15 2025-11-18 Axcess Global Sciences, Llc Autobiotic compositions and method for promoting healthy gut microbiome
US11950616B2 (en) 2019-06-21 2024-04-09 Axcess Global Sciences, Llc Non-vasoconstricting energy-promoting compositions containing ketone bodies
US12167993B2 (en) 2019-06-21 2024-12-17 Axcess Global Sciences, Llc Non-vasoconstricting energy-promoting compositions containing ketone bodies
US11969430B1 (en) 2023-03-10 2024-04-30 Axcess Global Sciences, Llc Compositions containing paraxanthine and beta-hydroxybutyrate or precursor for increasing neurological and physiological performance
US12186297B2 (en) 2020-08-26 2025-01-07 Axcess Global Sciences, Llc Compositions and methods for increasing lean-to-fat mass ratio

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4997976A (en) * 1988-11-15 1991-03-05 Henri Brunengraber Use of 1,3-butanediol acetoacetate in parenteral oral nutrition
AU1735800A (en) * 1998-11-19 2000-06-05 Charles E. Niesen Method of treating seizure disorders
US20070179197A1 (en) * 2000-05-01 2007-08-02 Accera, Inc. Compositions and methods for improving or preserving brain function
EP1793813A4 (fr) * 2004-09-21 2011-05-18 Btg Int Ltd Traitement du trouble d'hyperactivite avec deficit de l'attention (thada)
US7807718B2 (en) * 2006-06-30 2010-10-05 Sami A. Hashim Glyceride esters for the treatment of diseases associated with reduced neuronal metabolism of glucose
EP2143434A4 (fr) * 2007-03-30 2014-07-23 Earthus Inc Composition pour favoriser la formation d'un composé cétone
US20110111495A1 (en) * 2008-04-18 2011-05-12 Shanghai Cp Guojian Pharmaceutical Co. Ltd Concentrated medium and its usage

Also Published As

Publication number Publication date
FR2997302A1 (fr) 2014-05-02

Similar Documents

Publication Publication Date Title
FR2997302B1 (fr) Prevention et traitement des deficits en pyruvate deshydrogenase
IL237528A0 (en) Methods for preventing and treating preeclampsia
IL239355A0 (en) Compositions of gamma-hydroxybutyrate and their use in the treatment of disorders
BR112013024401A2 (pt) métodos e composições para o tratamento do transtorno do déficit de atenção
EP2831001A4 (fr) Compositions de traitement des eaux et procédés d'utilisation
EP2670434A4 (fr) Traitement de tauopathies
EP2906208A4 (fr) Traitement thérapeutique
EP2846809A4 (fr) Traitement de la myélosuppression
PL2830654T3 (pl) Sposoby i kompozycje do leczenia zapalenia
SI3646876T1 (sl) Uporaba inhibitorja telomeraze imetelstat za zdravljenje mieloproliferativnih motenj in mieloproliferativnih neoplazm
PL2919796T3 (pl) Zastosowanie bakterii akkermansia w leczeniu zaburzeń metabolicznych
EP2914261A4 (fr) Létalité synthétique et le traitement anticancéreux
DK2854910T3 (da) Ceramidniveauer i behandling og forebyggelse af infektioner
ZA201501503B (en) Bio-inoculant and use thereof for treatment of effluents
IL241555B (en) Preparations for the treatment of xerostomia and dental care
FR3000491B1 (fr) Composes utilisables dans le traitement des infections mycobacteriennes
EP2789289A4 (fr) Dispositif endoscopique et dispositif de traitement
EP2849566A4 (fr) Méthodes et compositions de traitement de la douleur
EP2841075A4 (fr) Agents et méthodes de traitement et de prévention des verrues séborrhéiques
EP2887947A4 (fr) Traitement de la drépanocytose et de troubles inflammatoires
FR2991585B1 (fr) Extrait de canneberge utile dans le traitement et la prevention des infections urinaires
ZA201307058B (en) Use of polyaminoisoprenyl derrivatives in antobiotic or antisertic treatment
EP2800568A4 (fr) Compositions, procédés d'utilisation et procédés de traitement
EP2726154A4 (fr) Prévention et traitement de conditions inflammatoires aiguës
FR2987267B1 (fr) Application du modafinil dans le traitement de substitution des cacainomanes

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 4

PLFP Fee payment

Year of fee payment: 5

PLFP Fee payment

Year of fee payment: 6

PLFP Fee payment

Year of fee payment: 7

PLFP Fee payment

Year of fee payment: 8

PLFP Fee payment

Year of fee payment: 9

PLFP Fee payment

Year of fee payment: 10

PLFP Fee payment

Year of fee payment: 11

PLFP Fee payment

Year of fee payment: 12

ST Notification of lapse

Effective date: 20250605